Dupixent® (Dupilumab) Demonstrated Superiority Over Xolair® (Omalizumab) in Chronic ...

Dupixent® (dupilumab) Demonstrated Superiority Over Xolair® (Omalizumab) in Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) in Patients with Coexisting Asthma in First-ever Presented Phase 4 Head-to-Head Respiratory Trial - Regeneron Pharmaceuticals (NA

New late-breaking data at EAACI showed Dupixent outperformed Xolair across all primary and secondary efficacy endpoints of CRSwNP and in all asthma-related endpoints Dupixent also outperformed Xolair in improving such key signs and symptoms as nasal polyp size and sense of smell in CRSwNP, and lung function and disease control in asthma, with rapid improvements seen as early as 4 weeks Results reinforce the efficacy of Dupixent in treating both …

Dupixent® (dupilumab) Demonstrated Superiority Over Xolair® (Omalizumab) in Chronic ...

New late-breaking data at EAACI showed Dupixent outperformed Xolair across all primary and secondary efficacy endpoints of CRSwNP and in all asthma-related endpoints

Product News for June 2025

Discover the latest FDA-approved treatments, including Dupixent for chronic urticaria and Valtoco for seizure clusters, enhancing patient care options.

Dupilumab Shows Superiority Over Omalizumab for Chronic Rhinosinusitis

This study is the first to compare 2 biologics for patients with chronic rhinosinusitis with nasal polyps and coexisting asthma.

Press Release: EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase 4 head-to-head respiratory study

EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase 4 head-to-head respiratory study New late-breaking data at EAACI showed Dupixent outperformed Xolair across all primary and secondary efficacy endpoints of CRSwNP and in all asthma-related endpoints Dupixent also outperformed Xolair in improving […] The post Press Release: …

Dupixent bests Xolair in first head-to-head respiratory trial

On the heels of announcing positive data for Dupixent (dupilumab) in atopic dermatitis patients with darker skin tones, Sanofi and Regeneron have announced that the monoclonal antibody outperformed Xolair (omalizumab) in the phase 4 EVEREST trial. Marking the first head-to-head comparison of biologic respiratory medicines, the study focused on patients with severe chronic rhinosinusitis with… The post Dupixent bests Xolair in first head-to-head …